2-(trifluoroacetyl)-2,3-dihydro-1H-isoindole-5-sulfonyl chloride | 1374655-15-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(trifluoroacetyl)-2,3-dihydro-1H-isoindole-5-sulfonyl chloride
• 英文别名: 2-(2,2,2-Trifluoroacetyl)isoindoline-5-sulfonyl chloride；2-(2,2,2-trifluoroacetyl)-1,3-dihydroisoindole-5-sulfonyl chloride
• CAS: 1374655-15-8
• 化学式: C₁₀H₇ClF₃NO₃S
• 分子量: 313.685
• InChiKey: ASCZCPBZJKTBKC-UHFFFAOYSA-N

物化性质

• 沸点：
  451.8±45.0 °C(Predicted)
• 密度：
  1.617±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(trifluoroacetyl)-2,3-dihydro-1H-isoindole-5-sulfonyl chloride 在 吡啶 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-(2-(3-methoxyphenyl)acetyl)-N-(2-phenyl-2H-1,2,3-triazol-4-yl)isoindoline-5-sulfonamide
  参考文献：
  名称：

  Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3

  摘要：

  Inhibition of triacylglycerol (TAG) biosynthetic enzymes has been suggested as a promising strategy to treat insulin resistance, diabetes, dyslipidemia, and hepatic steatosis. Monoacylglycerol acyltransferase 3 (MGAT3) is an integral membrane enzyme that catalyzes the acylation of both monoacylglycerol (MAG) and diacylglycerol (DAG) to generate DAG and TAG, respectively. Herein, we report the discovery and characterization of the first selective small molecule inhibitors of MGAT3. Isoindoline-5-sulfonamide (6f, PF-06471553) selectively inhibits MGAT3 with high in vitro potency and cell efficacy. Because the gene encoding MGAT3 (MOGAT3) is found only in higher mammals and humans, but not in rodents, a transgenic mouse model expressing the complete human MOGAT3 was used to characterize the effects of 6f in vivo. In the presence of a combination of diacylglycerol acyltransferases 1 and 2 (DGAT1 and DGAT2) inhibitors, an oral administration of 6f exhibited inhibition of the incorporation of deuterium-labeled glycerol into TAG in this mouse model. The availability of a potent and selective chemical tool and a humanized mouse model described in this report should facilitate further dissection of the physiological function of MGAT3 and its role in lipid homeostasis.

  DOI：

  10.1021/acs.jmedchem.5b01008
• 作为产物：
  描述：

  1-(1,3-dihydro-2H-isoindol-2-yl)-2,2,2-trifluoroethanone 在 氯磺酸 作用下， 以 二氯甲烷 为溶剂， 以72%的产率得到2-(trifluoroacetyl)-2,3-dihydro-1H-isoindole-5-sulfonyl chloride
  参考文献：
  名称：

  Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3

  摘要：

  Inhibition of triacylglycerol (TAG) biosynthetic enzymes has been suggested as a promising strategy to treat insulin resistance, diabetes, dyslipidemia, and hepatic steatosis. Monoacylglycerol acyltransferase 3 (MGAT3) is an integral membrane enzyme that catalyzes the acylation of both monoacylglycerol (MAG) and diacylglycerol (DAG) to generate DAG and TAG, respectively. Herein, we report the discovery and characterization of the first selective small molecule inhibitors of MGAT3. Isoindoline-5-sulfonamide (6f, PF-06471553) selectively inhibits MGAT3 with high in vitro potency and cell efficacy. Because the gene encoding MGAT3 (MOGAT3) is found only in higher mammals and humans, but not in rodents, a transgenic mouse model expressing the complete human MOGAT3 was used to characterize the effects of 6f in vivo. In the presence of a combination of diacylglycerol acyltransferases 1 and 2 (DGAT1 and DGAT2) inhibitors, an oral administration of 6f exhibited inhibition of the incorporation of deuterium-labeled glycerol into TAG in this mouse model. The availability of a potent and selective chemical tool and a humanized mouse model described in this report should facilitate further dissection of the physiological function of MGAT3 and its role in lipid homeostasis.

  DOI：

  10.1021/acs.jmedchem.5b01008

文献信息

• Nitrogen-containing condensed heterocyclic compound
  申请人：Busujima Tsuyoshi

  公开号：US09035059B2

  公开（公告）日：2015-05-19

  There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein Ring A represents a partially saturated heteroaryl group, an aryl group or a heteroaryl group, RB represents a C4-18 alkyl group, a C3-8 cycloalkyl group, a partially saturated aryl group, an aryl group, or the following formula (II): wherein V represents the formula —CR11R12—, —CO—, —CO—O—, or —CO—NH—, W represents a single bond or a C1-3 alkylene group, and Ring B represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a partially saturated heteroaryl group, a saturated heterocyclyl group, an aryl group, or a heteroaryl group, Y represents a nitrogen atom or the formula N+(RF), RF represents a C1-4 alkyl group, and m and n, which may be the same or different, each represent an integer of 0 or 1.

  提供以下通式（I）表示的化合物或其药学上可接受的盐，具有优越的单酰基甘油酰基转移酶2抑制作用：其中，环A代表部分饱和的杂环基，芳基或杂芳基，RB代表C4-18烷基，C3-8环烷基，部分饱和的芳基，芳基或以下式（II）：其中，V代表式—CR11R12—，—CO—，—CO—O—或—CO—NH—，W代表单键或C1-3烷基，环B代表C3-8环烷基，C3-8环烯基，部分饱和的杂环基，饱和杂环基，芳基或杂芳基，Y代表氮原子或式N+（RF），RF代表C1-4烷基，m和n分别表示0或1，可以相同也可以不同。
• NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：EP2687507B1

  公开（公告）日：2016-03-09
• Identification of 2-[2-(4- tert -butylphenyl)ethyl]- N -(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide ( 29 ) as an orally available MGAT2 inhibitor
  作者：Tsuyoshi Busujima、Hiroaki Tanaka、Yoshihisa Shirasaki、Eiji Munetomo、Masako Saito、Kiyokazu Kitano、Toshiya Minagawa、Koji Yoshida、Naoto Osaki、Nagaaki Sato

  DOI：10.1016/j.bmc.2015.06.065

  日期：2015.9

  MGAT2 (monoacylglycerol acyltransferase 2) is expected to be an attractive target for the drug treatment of obesity, diabetes, and other disease. We describe our exploration and structure-activity relationship (SAR) study of 2,3-dihydro-1H-isoindole-5-sulfonamide derivatives. In this study, we identified 29 as an orally available inhibitor of MGAT2 through optimization especially in terms of solubility. This compound exhibited moderate potency in the enzyme inhibitory assay (IC50 = 1522 nM) and significant suppression of fat absorption (57% inhibition) in mice oral lipid tolerance test. (C) 2015 Elsevier Ltd. All rights reserved.
• US9035059B2
  申请人：——

  公开号：US9035059B2

  公开（公告）日：2015-05-19
• Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3
  作者：Kim Huard、Allyn T. Londregan、Gregory Tesz、Kevin B. Bahnck、Thomas V. Magee、David Hepworth、Jana Polivkova、Steven B. Coffey、Brandon A. Pabst、James R. Gosset、Anu Nigam、Kou Kou、Hao Sun、Kyuha Lee、Michael Herr、Markus Boehm、Philip A. Carpino、Bryan Goodwin、Christian Perreault、Qifang Li、Csilla C. Jorgensen、George T. Tkalcevic、Timothy A. Subashi、Kay Ahn

  DOI：10.1021/acs.jmedchem.5b01008

  日期：2015.9.24

  Inhibition of triacylglycerol (TAG) biosynthetic enzymes has been suggested as a promising strategy to treat insulin resistance, diabetes, dyslipidemia, and hepatic steatosis. Monoacylglycerol acyltransferase 3 (MGAT3) is an integral membrane enzyme that catalyzes the acylation of both monoacylglycerol (MAG) and diacylglycerol (DAG) to generate DAG and TAG, respectively. Herein, we report the discovery and characterization of the first selective small molecule inhibitors of MGAT3. Isoindoline-5-sulfonamide (6f, PF-06471553) selectively inhibits MGAT3 with high in vitro potency and cell efficacy. Because the gene encoding MGAT3 (MOGAT3) is found only in higher mammals and humans, but not in rodents, a transgenic mouse model expressing the complete human MOGAT3 was used to characterize the effects of 6f in vivo. In the presence of a combination of diacylglycerol acyltransferases 1 and 2 (DGAT1 and DGAT2) inhibitors, an oral administration of 6f exhibited inhibition of the incorporation of deuterium-labeled glycerol into TAG in this mouse model. The availability of a potent and selective chemical tool and a humanized mouse model described in this report should facilitate further dissection of the physiological function of MGAT3 and its role in lipid homeostasis.